Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes

NCT02416765 | Completed Phase 2

• 1 other identifier: CLASS10
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Postprandial meal glucose control with closed-loop systems (CLS) still needs some improvements. In the postprandial period, sensor delay in detecting blood glucose rise after a meal together with delays in insulin absorption expose patients to early risk of hyperglycemia and then to late-postprandial hypoglycemia. Glucagon infusion in dual-hormone CLS has the potential to improve post-meal control as compared to single-hormone CLS allowing a better glucose excursion related to a more aggressive insulin infusion while minimizing hypoglycemic risk. Several approaches have been tested for the determination of prandial boluses during closed-loop operation. The objective of this study is to test in outpatient unrestricted settings whether, in the context of closed-loop strategy, conventional meal carbohydrate counting could be reduced to a simplified qualitative meal size estimation without a significant degradation in overall glycemic control in adult patients with type 1 diabetes. The investigators hypothesize that in outpatient free-living conditions: 1) Dual-hormone CLS with partial boluses is equivalent to dual-hormone CLS with full boluses in terms of mean glucose; 2) Single-hormone CLS with partial boluses is equivalent to single-hormone CLS with full boluses in terms of mean glucose. Secondary hypothesis are: 3) Dual-hormone CLS with partial boluses will decrease time in hypoglycemia compared to single-hormone CLS with partial boluses; 4) Dual-hormone CLS with partial boluses is better than sensor-augmented pump therapy in terms of mean glucose; 5) Single-hormone CLS with partial boluses is better than sensor-augmented pump therapy in terms of mean glucose.

Conditions

Type 1 Diabetes

Keywords

Closed-loop strategy; Artificial pancreas; Postprandial glucose; Insulin; Glucagon; Hypoglycemia; Type 1 diabetes

Outcome Measures

Primary Outcomes (1)

• Mean glucose levels as measured by the glucose sensor.

  The following comparisons will be done: 1) Dual-hormone CLS with partial boluses vs. dual-hormone CLS with full boluses; 2) Single-hormone CLS with partial boluses vs. single-hormone CLS with full boluses.

  15 hours

Secondary Outcomes (15)

• Mean glucose levels as measured by the glucose sensor

  15 hours

• Percentage of time of sensor glucose concentrations between 4 and 8 mmol/L

  15 hours

• Percentage of time of sensor glucose concentrations between 4 and 10 mmol/L

  15 hours

• Percentage of time of sensor glucose concentrations above 10 mmol/L

  15 hours

• Percentage of time of sensor glucose concentrations above 14 mmol/L

  15 hours

Study Arms (5)

Sensor-augmented pump therapy

ACTIVE COMPARATOR

Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.

Other: 15-hour intervention

Single-hormone CLS with full boluses

ACTIVE COMPARATOR

Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.

Other: 15-hour intervention; Drug: Insulin (Lispro, Aspart or guilisine); Other: Closed-loop strategy

Single-hormone CLS with partial boluses

ACTIVE COMPARATOR

Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.

Other: 15-hour intervention; Drug: Insulin (Lispro, Aspart or guilisine); Other: Closed-loop strategy

Dual-hormone CLS with full boluses

ACTIVE COMPARATOR

Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.

Other: 15-hour intervention; Drug: Insulin (Lispro, Aspart or guilisine); Drug: Glucagon (Eli Lilly); Other: Closed-loop strategy

Dual-hormone CLS with partial boluses

ACTIVE COMPARATOR

Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.

Other: 15-hour intervention; Drug: Insulin (Lispro, Aspart or guilisine); Drug: Glucagon (Eli Lilly); Other: Closed-loop strategy

Interventions

15-hour intervention OTHER

Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.

Dual-hormone CLS with full boluses; Dual-hormone CLS with partial boluses; Sensor-augmented pump therapy; Single-hormone CLS with full boluses; Single-hormone CLS with partial boluses

Insulin (Lispro, Aspart or guilisine) DRUG

Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.

Dual-hormone CLS with full boluses; Dual-hormone CLS with partial boluses; Single-hormone CLS with full boluses; Single-hormone CLS with partial boluses

Glucagon (Eli Lilly) DRUG

In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.

Dual-hormone CLS with full boluses; Dual-hormone CLS with partial boluses

Closed-loop strategy OTHER

Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.

Dual-hormone CLS with full boluses; Dual-hormone CLS with partial boluses; Single-hormone CLS with full boluses; Single-hormone CLS with partial boluses

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females ≥ 18 years old.
• Clinical diagnosis of type 1 diabetes for at least one year.
• The subject will have been on insulin pump therapy for at least 3 months and currently using a fast actin insulin analog (Lispro, Aspart or Guilisine).
• Last (less than 3 months) HbA1c ≤ 10%.
• Currently using carbohydrate counting as the meal insulin dose strategy.

You may not qualify if:

• Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.
• Recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
• Ongoing pregnancy.
• Severe hypoglycemic episode within 1 month of screening.
• Agents affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months. Otherwise, these medications are acceptable and will be kept stable during the entire protocol.
• Oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef®). Inhale steroids at stable dose in the last month are acceptable.
• Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator (e.g. unstable psychiatric condition).
• Failure to comply with team's recommendations (e.g. not willing to change pump parameters, follow algorithm's suggestions, etc).
• Living or planned travel outside Montreal (\> 1h of driving) area during closed-loop procedures.

Sponsors & Collaborators

• Institut de Recherches Cliniques de Montreal: lead

Study Sites (1)

Institut de recherches cliniques de Montréal

Montreal, Quebec, H2W1R7, Canada

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1; Insulin Resistance; Hypoglycemia

Interventions

Methods; Insulin; Insulin Lispro; Insulin Aspart; Glucagon

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Hyperinsulinism

Intervention Hierarchy (Ancestors)

Investigative Techniques; Proinsulin; Insulins; Pancreatic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Insulin, Short-Acting; Proglucagon

Study Officials

• Rémi Rabasa-Lhoret

  Institut de recherches cliniques de Montréal

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, PhD

Study Record Dates

• First Submitted: April 2, 2015
• First Posted: April 15, 2015
• Study Start: May 1, 2015
• Primary Completion: October 1, 2015
• Study Completion: October 1, 2015
• Last Updated: November 16, 2015

Record last verified: 2015-11

Locations

CA (1)